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Abstract. Aim: To identify patients with breast cancer at
risk for cardiotoxicity, we evaluated homoarginine (HA)
behavior during adjuvant treatment. Patients and Methods:
Eighty-one patients received radiotherapy (RT) with or
without endocrine treatment, and 19 received chemotherapy,
RT and endocrine therapy. Serum HA, asymmetric
dimethylarginine (ADMA) and high-sensitivity cardiac
troponin T (hscTnT) were measured and echocardiography
was performed before chemotherapy, and before and after
RT. Results: In chemo-naïve tamoxifen users HA increased
during RT from a median (IQR) of 2.47 (1.61-3.35) to 2.86
(1.93-4.23) μM (p=0.028) and remained stable in patients
with aromatase inhibitor and in those without endocrine
therapy. Tamoxifen users were mostly spared from
echocardiographic changes. In chemotherapy-treated
patients, HA decreased during chemotherapy (p=0.001) from
1.46 (1.01-2.18) to 0.91 (0.71-1.29) μM, and increased
(p=0.004) to 1.19 (0.83-1.63) μM during RT, remaining
lower than at baseline (p=0.014). Echocardiographic
changes were observed during chemotherapy. Conclusion:
HA decrease during chemotherapy could indicate an
increased risk of cardiovascular morbidity. Additionally, HA
increase in tamoxifen users may reflect a cardioprotective
effect of tamoxifen.
In order to lower the risk of recurrence and death from early
breast cancer, patients receive adjuvant treatments. However,
cardiotoxicity, manifesting years later, is associated with all
forms of adjuvant treatment: chemotherapy, radiotherapy
(RT) and endocrine therapy (1-6). Furthermore, a recent
meta-analysis concluded that the 19% increase in risk of
cardiovascular events with aromatase inhibitor (AI) use
relative to tamoxifen was most likely a reflection of the
cardioprotective effect of tamoxifen (7).
Low levels of the cardiac biomarker, homoarginine (HA),
have been associated with an increased risk of cardiovascular
events, and increased cardiac and all-cause mortality, in
patients with various heart conditions in population-based
studies (8-14). An association of low HA with impaired
cardiac function has also been documented, namely, with a
lowered left ventricular ejection fraction (LVEF) and
diastolic dysfunction in patients with preserved LVEF (8,
15). In contrast, an elevated level of another cardiac
biomarker, asymmetric dimethylarginine (ADMA), is
associated with increased cardiovascular risk (16). Although
an epidemiological study found no association between HA
and cancer-specific mortality, the effect of cancer treatments
on HA level has not been reported to our knowledge (12).
The aim of our study was to investigate changes in cardiac
biomarkers, HA, ADMA and high-sensitivity cardiac troponin-
T (hscTnT), and in echocardiographic measurements during
and after adjuvant therapy of early breast cancer to find
patients at risk for later cardiovascular complications. 
Patients and Methods 
Patient population. This single-center, prospective, observational
clinical study included 100 patients with measurable serum samples
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who received adjuvant treatment for breast cancer or ductal
carcinoma in situ between June 2011 and May 2013. All patients
received postoperative RT after breast-conserving surgery or
mastectomy. Patients were grouped according to chemotherapy and
endocrine therapy (Figure 1). Exclusion criteria were described
previously, with the exception of the inclusion of chemotherapy-
receiving patients in this study (17). The protocol was approved by
the local Ethics Committee (R10160) and informed consent was
obtained from all individual participants included in the study.
Chemotherapy. The most common chemotherapy regimen used was
three courses of docetaxel (80 mg/m2), followed by three courses of
CEF (600 mg/m2 fluorouracil, 75 mg/m2 epirubicin and 600 mg/m2
cyclophosphamide; n=20). Other regimens used were six courses of
CEF (n=4); four courses of docetaxel (75 mg/m2) and
cyclophosphamide (600 mg/m2) (n=1); or three courses of docetaxel
(60 mg/m2) and capecitabine (900 mg/m2 twice daily on days 1-15)
followed by three courses of cyclophosphamide (600 mg/m2),
epirubicin (75 mg/m2) and capecitabine (900 mg/m2 twice daily on
days 1-15) (n=3). All cytotoxic agents, except capecitabine, were
administered intravenously on day one of the 21-day treatment cycle
(18-20). One patient also received trastuzumab (8 mg/kg loading dose
and 6 mg/kg thereafter) together with docetaxel. 
Radiotherapy. Execution of the RT was described in detail in earlier
publications (17, 21). The treatment dose was either 50 Gy in 2-Gy
fractions with or without an additional boost of 10-16 Gy in 2-Gy
fractions to the tumor bed or 42.56 Gy in 2.66-Gy fractions over 3.5
weeks (hypofractionation). Axillary or supraclavicular lymph nodes
were included in the planning target volume according to local
guidelines. 
Serum biomarker analysis. Serum samples were taken before
commencing chemotherapy, if applicable, before RT, 2 weeks (for
hypofractionated RT) or 3 weeks (for conventional RT) after the
start of RT and the last day of RT. Serum samples were subjected
to solid-phase extraction (Oasis® MCX SPE columns; Waters,
Milford, MA, USA) as described previously (22). L-NG-
Monomethyl arginine was used as internal standard. Eluted samples
were dried under nitrogen at 55˚C and the residues were dissolved
in 0.1 mL ultrapure water and stored at −20˚C. Chromatography was
performed on a Symmetry® C18 column (4.6×150 mm, 5 μm) with
Symmetry® C18 guard column (3.9×20 mm) (Waters) as described
previously (23) using a Shimadzu liquid chromatography system
(Shimadzu, Kyoto, Japan) with a gradient pump (LC-10AD), an
autosampler (SIL-30AC) and fluorescence detector (RF-10Axl).
Data acquisition and analysis were performed using LabSolutions
software (Shimadzu), and ADMA and HA concentrations in samples
were calculated against standard curves. The detection limits and
inter-assay coefficients of variation for AMDA were 0.078 μM and
4.9%, respectively, and 0.078 μM and 1.7% for HA.
High sensitivity cardiac troponin T was measured at the same
time points as HA and ADMA. The detection limit was 5 ng/l and
values below this were estimated to be 4 ng/l.
Echocardiographic examination. Echocardiographic examination
was performed before the beginning of chemotherapy, before the
start of RT and after completion of RT by a single cardiologist (ST)
using a commercially available ultrasound machine (Philips iE33
ultrasound system; Philips, Bothell, WA, USA) and a 1-5 MHz
matrix-array X5-1 transducer in a standardized manner as described
previously (24), following current guidelines (25-28). 
Statistical analysis. Chemo-naïve patients and chemotherapy-treated
patients were analyzed separately. Furthermore, patients were
divided into subgroups by endocrine therapy. Due to the skewed
distributions of all continuous variables, medians and interquartile
ranges were calculated. To test differences in baseline
characteristics, Fisher’s exact test and the Mann–Whitney U-test
were used for catecorical and continuous variables, respectively.
Linear regression was used to determine statin use as a predictor of
change in HA during RT in chemo-naïve patients. In order to test
for changes in HA, ADMA, hscTnT and echocardiographic
parameters during chemotherapy and RT, the Friedman and
Wilcoxon signed-rank tests were utilized. Group based trajectory
modeling was used to created trajectory groups of chemo-naïve
patients for HA (29). The trajectory groups were created according
to all measurements of HA in each patient as a continuous outcome
measure and the groups represent clusters of individuals with
similar trajectories and outcomes over time (30). Models were fitted
by using the flexmix package (31) of the statistical program R,
version 3.3.0, from the R Foundation for Statistical Computing (32).
Relative goodness of fit was assessed using Bayesian information
criteria (BIC). Odds ratio (OR) for the trajectory groups was
determined by multinomial logistic regression. Statistical analyses
were performed using IBM SPSS statistics for Windows (version
23, IBM Corp., Armonk, NY, USA). p-Values under 0.05 were
considered statistically significant.
Results
Baseline characteristics. Baseline characteristics of all
treated patients and groups according to oncological
intervention are described in Table I. Patients receiving
chemotherapy were younger (p=0.002) and more likely to
receive tamoxifen (p=0.010) or AI (p=0.019) than chemo-
naïve patients. However, baseline HA levels were similar
(p=0.772). The baseline ADMA level was significantly
higher (p<0.001) in chemo-naïve patients than in
chemotherapy-receiving patients, albeit the absolute levels
were similar, at 0.40 and 0.39, respectively. 
Patients without endocrine therapy had a lower body mass
index (BMI) than tamoxifen users (p=0.033) or AI users
(p=0.003) (Table II). Tamoxifen users used angiotensin-
converting enzyme inhibitors more often than those without
endocrine therapy (p=0.031).The baseline HA level was
significantly higher in tamoxifen users than in AI users
(p=0.029) and those without endocrine therapy (p=0.016).
The ADMA level, on the other hand, tended to be lower in
tamoxifen users than in AI users (p=0.076) and those
without endocrine therapy (p=0.054). 
Homoarginine changes during RT in chemo-naïve patients.
HA remained stable in the 81 patients who received RT but
no chemotherapy, 1.58 (1.12-2.035) μM before RT and 1.60
(0.98-2.035) μM after RT (p=0.822) (Figure 2a). Analysis
was also performed according to tamoxifen use. As baseline
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Figure 1. Flow chart of patients included in the study. DCIS: Ductal carcinoma in situ, RT: radiotherapy, AI: aromatase inhibitor, Tam: tamoxifen.
Table I. Baseline characteristics of the study population.
Characteristic                                                 All treated (n=100)                      Chemo + RT (n=19)                      RT only (n=81)                    p-Value*
Median age (IQR), years                                      62 (58-66)                                     58 (50-61)                                  64 (58-66)                          0.002
Median BMI (IQR), kg/m2                           25.95 (24.10-28.95)                      24.90 (23.10-28.15)                   26.20 (24.21-29.31)                  0.195
Current smoker, n (%)                                             14 (14)                                          4 (21.1)                                     10 (12.3)                           0.460
Statin use, n (%)                                                      18 (18)                                           1 (5.3)                                        17 (21)                             0.183
Hypertension, n (%)                                                37 (37)                                          5 (26.3)                                     32 (39.5)                           0.429
CAD, n (%)                                                                4 (4)                                             1 (5.3)                                        3 (3.7)                             0.576
ACE or ARB, n (%)                                                27 (27)                                          3 (15.8)                                     24 (29.6)                           0.265
Hypothyreosis, n (%)                                               15 (15)                                          3 (15.8)                                     12 (14.8)                           1.000
ASA, n (%)                                                                8 (8)                                               0 (0)                                          8 (9.9)                             0.347
Beta-blockers, n (%)                                                15 (15)                                          3 (15.8)                                     12 (14.8)                           1.000
AI, n (%)                                                                  43 (43)                                         13 (68.4)                                      30 (37)                             0.019
Tamoxifen, n (%)                                                     12 (12)                                          6 (31.6)                                       6 (7.4)                             0.010
Median HA (IQR), μM                                    1.56 (1.10-2.08)                            1.46 (1.01-2.18)                        1.58 (1.12-2.035)                     0.772
Median ADMA (IQR), μM                               0.39 (0.3-0.42)                             0.39 (0.33-0.44)                         0.40 (0.37-0.44)                   <0.001
Median hscTnT (IQR), ng/l,                              4.0 (4.0-6.0)                                  4.0 (4.0-4.0)                              4.0 (4.0-6.75)                        0.181
Chemo: Chemotherapy, RT: radiotherapy, IQR: interquartile range, BMI: body mass index, CAD: coronary artery disease, ACE: angiotensin-
converting enzyme inhibitors, ARB: angiotensin II receptor blockers, ASA: low-dose acetylsalicylic acid, AI: aromatase inhibitor use, HA:
homoarginine, ADMA: asymmetric dimethylarginine, hscTnT: high-sensitivity cardiac troponin-T. *Mann–Whitney U-test for non-normal variables,
Fischer’s exact test for categorical variables to compare chemo + RT and radiotherapy-only groups.
HA values and the change in HA levels were similar in AI
users and in those without endocrine therapy, these patients
were analyzed together as one group. Tamoxifen users had a
higher median HA of 2.47 (1.61-3.35) μM before starting RT
compared to the median HA of 1.53 (1.1-1.95) μM in non
users (p=0.017). The HA level also increased significantly
by 0.47 (0.31-0.89) μM (p=0.028) in tamoxifen users
(Figure 2b), whereas the change of −0.03 (−0.25-0.1) μM
(p=0.231) in non users was not significant (Figure 2c). In
linear regression analysis, statin use was a significant factor
predicting the change in HA. Statin use did not affect the
baseline HA value, which was 1.50 (0.98-2.17) μM in statin
users and 1.60 (1.14-1.98) μM in non users (p=0.826), but
there was a significant increase of HA by 0.1 (0.01-0.56) μM
(p=0.014) in statin users and a non-significant change of
−0.1 (−0.33-0.14) μM (p=0.123) in non users during RT. 
The chemo-naive patients were also divided into
trajectories by HA behavior (Figure 3). Group 1 included
four out of 11 (36%) tamoxifen users and group 2 included
two out of 43 (4.7%) tamoxifen users. There were no
tamoxifen users among the 27 patients in group 3. The odds
ratio for tamoxifen use was 11.71 (95% confidence
interval=1.79-76.55) between groups 1 and 3.
Homoarginine changes in patients receiving chemotherapy.
The median HA values, in Figure 4, for the 19 patients who
received both chemotherapy and RT were 1.46 (1.01-2.18) μM,
0.91 (0.71-1.29) μM and 1.19 (0.83-1.63) μM before
chemotherapy, before RT and after RT, respectively. The
changes in HA during chemotherapy and RT were significant
(p<0.001 Figure 4). HA values decreased by 0.52 μM during
chemotherapy (p=0.001) and increased by 0.20 μM during RT
(p=0.004), but did not recover to baseline levels. HA levels
remained 0.27 (−0.37-0.02) μM lower at the end of RT
compared to baseline levels before chemotherapy (p=0.014). 
All of these 19 patients received endocrine therapy, six
with tamoxifen and 13 with AI. The baseline values and the
decrease in HA levels during chemotherapy were similar in
tamoxifen and AI users. During the RT following
chemotherapy, HA values increased by a median of 0.71
(0.09-1.26) μM (p=0.075) in tamoxifen users and by 0.15
(0.03-0.38) μM (p=0.023) in AI users. HA values at the end
of RT were 1.48 (1.14-2.81) μM in tamoxifen users and 0.96
(0.78-1.43) μM in AI users. Although, the difference in end
values was only borderline significant, p=0.058, between the
groups, HA levels remained significantly lower in AI users
(p=0.002) than the baseline HA values. In tamoxifen users,
there was no significant difference in HA levels between
baseline and after RT (p=0.753).
Asymmetric dimethylarginine (ADMA). In chemo-naïve
patients, the median ADMA levels were 0.40 (0.37-0.44) μM
and 0.41 (0.35-0.45) μM before and after RT, respectively and
they remained stable throughout RT (p=0.569). ADMA levels
were compared according to tamoxifen use and the baseline
levels tended to be lower (p=0.050) in tamoxifen users (Table
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Table II. Baseline characteristics of patients receiving radiotherapy (RT) and tamoxifen, aromatase inhibitor (AI) or no endocrine therapy.
                                                                                                         Radiotherapy                               
Characteristic                                              Tamoxifen (n=6)            AI (n=30)          No endocrine therapy (n=45)     p-Value1       p-Value2     p-Value3
Median age (IQR), years                           64 (56.75-69.25)           64 (58-67)                         62 (58-66)                       0.951            0.638           0.458
Median BMI, kg/m2, (IQR)                       30.4 (25.7-33.2)       27.4 (24.9-30.3)                24.8 (23.6-27.4)                   0.448            0.033           0.003
Current smoker, n (%)                                         0 (0)                       5 (16.7)                             5 (11.1)                          0.564            1.000           0.508
Statin use, n (%)                                                2 (33.3)                     8 (26.7)                             7 (15.6)                          1.000            0.284           0.255
hypertension, n (%)                                           4 (66.7)                    13 (43.3)                           15 (33.3)                         0.391            0.179           0.467
CAD, n (%)                                                          0 (0)                        1 (3.3)                               2 (4.4)                           1.000            1.000           1.000
ACE or ARB, n (%)                                          4 (66.7)                    11 (36.7)                            9 (20.0)                          0.210            0.031           0.121
Hypothyreosis, n (%)                                        1 (16.7)                     6 (20.0)                             5 (11.1)                          1.000            0.548           0.330
ASA, n (%)                                                        1 (16.7)                     5 (16.7)                              2 (4.4)                           1.000            0.319           0.108
Beta-blockers, n (%)                                         1 (16.7)                     7 (23.3)                              4 (8.9)                           1.000            0.480           0.104
Median mean heart dose, (IQR)                1.74 (0.62-4.17)       2.30 (1.06-3.75)                2.02 (0.80-3.68)                   0.749            0.831           0.799
Median baseline HA, (IQR), μM               2.47 (1.61-3.35)       1.59 (1.12-1.96)                1.52 (1.09-1.95)                   0.029            0.016           0.996
Median baseline ADMA (IQR), μM          0.37 (0.32-0.39)       0.41 (0.37-0.44)                0.40 (0.37-0.45)                   0.076            0.054           0.872
Median baseline hscTnT (IQR), ng/l           4.5 (4.0-17.3)            5.0 (4.0-8.0)                      4.0 (4.0-6.0)                      0.782            0.414           0.157
AI: Aromatase inhibitor use, IQR: interquartile range, BMI: body mass index, CAD: coronary artery disease, ACE: angiotensin-converting enzyme
inhibitors, ARB: angiotensin II receptor blockers, ASA: low-dose acetylsalicylic acid, HA: homoarginine, ADMA: asymmetric dimethylarginine,
hscTnT: high-sensitivity cardiac troponin-T. 1Tamoxifen vs. AI, 2tamoxifen vs. no endocrine therapy, 3AI vs. no endocrine therapy. Mann–Whitney
U-test for non-normal variables, Fischer’s exact test for categorical variables.
II) than in non users [0.40 (0.37-0.44) μM]. The difference
persisted and became significant at the end of radiotherapy
(p=0.044), with ADMA levels of 0.35 (0.31-0.38) μM in
tamoxifen users and 0.41 (0.37-0.45) μM in non users.
In patients receiving chemotherapy and RT, the median
ADMA levels were 0.39 (0.33-0.44) μM, 0.41 (0.31-0.47)
μM and 0.37 (0.32-0.42) μM at baseline, and before RT and
after RT, respectively (p=0.215). The median change in
ADMA was 0.02 (−0.02-0.05) μM during chemotherapy
(p=0.146) and −0.02 (−0.056-0.01) μM during radiotherapy
(p=0.076). Neither tamoxifen nor AI use significantly
affected levels of or changes in ADMA in chemotherapy-
receiving patients.
High-sensitivity cardiac troponin T. We reported
radiotherapy-induced changes in hscTnT in chemo-naïve
patients with left-sided breast cancer in a previous
publication (21). The current study population also included
patients with right-sided breast cancer and in this population,
hscTnT remained stable, 4 (4-6.75) ng/l before RT and 5 (4-
7.5) ng/l after RT (p=0.116). Endocrine therapy did not
affect baseline TnT or the change in hscTnT. 
In patients receiving chemotherapy, hscTnT increased
during chemotherapy from 4 (4-4) ng/l to 9 (7-14) ng/l and
continued to increase during RT up to 13 (9-16) ng/l.
Endocrine therapy did not affect the hscTnT level, which
was similar before chemotherapy, before RT and after RT in
tamoxifen and AI users alike. Regardless, during RT, the
increase in hscTnT from 13 (8.5-13) ng/l to 14 (8-27.5) ng/l
was not significant (p=0.750), whereas in AI users the
increase from 9 (7-10.5) ng/l to 12 (9-17) ng/l was
significant (p=0.006).
Echocardiographic measurements. The detailed echocardio-
graphic changes in the chemo-naïve study population have
been described in previous publications (33, 34). Table III
shows a previously unpublished comparison of the
echocardiographic changes according to endocrine therapy of
patients with measurable serum samples. At baseline, AI users
had lower septal cyclic variation of the integrated backscatter
(CVIBS) and higher septal integrated backscatter in end-
diastole calibrated to the pericardium (cIBS) than tamoxifen
users and those without endocrine therapy. The six patients
using tamoxifen had the only significant change in CVIBS
(p=0.046), whereas AI users had significant changes in
tricuspid annular plane systolic excursion (TAPSE), global
longitudinal strain in speckle tracking analysis (GLS) and
mitral inflow E-wave peak velocity in pulsed Doppler analysis
(mitral E) and those without endocrine therapy had significant
changes in CVIBS, cIBS, TAPSE, interventricular septum
thickness (IVS) and posterior wall (PW) (Table III).
Eleven patients with left-sided breast cancer receiving
chemotherapy had an echocardiographic examination
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Figure 2. Homoarginine (HA) levels in patients before and after
radiotherapy (RT). The HA level in all chemo-naïve patients remained
stable after RT (a). The HA level before RT was higher in tamoxifen
users (b) compared to aromatase inhibitor users and those without
endocrine therapy (c); while HA increased in tamoxifen users during
RT, it remained stable in non-tamoxifen users.
performed before chemotherapy, before RT and after RT.
During chemotherapy, there was a significant increase in
tricuspid regurgitation peak gradient (Tr grad) (n=10,
p=0.042) from 18.5 (13.3.-21.3) mm to 20.5 (19.0-22.5) mm,
an increase in left ventricular end-systolic diameter (LVESD)
(n=10, p=0.041) from 31.2 (27.8-32.7) mm to 33.0 (30.7-
33.5) mm, an increase in PW (n=10, p=0.032) from 9.0 (8.3-
9.6) mm to 9.6 (9.0-11.0) mm, and a decrease in CVIBS
(n=10, p=0.037) from 11.92 (9.03-14.30) dB to 9.73 (6.62-
11.40) dB. During RT, there were no significant changes in
echocardiography in these 11 patients. Although RT did not
significantly affect LVESD measurement, LVESD did not
return to the baseline level but remained significantly
increased at 32.7 (30.7-33.0) mm compared to baseline
measurements (p=0.041). Endocrine therapy did not affect
echocardiographic measurements in these patients. 
Discussion
Homoarginine mechanism. Homoarginine and ADMA are
thought to be involved in the early process of atherosclerosis
through their role in the regulation of nitric oxide (NO)
production. An imbalance in NO and reactive oxygen species
production, in turn, seems to lead to endothelial dysfunction,
which contributes to the early process of atherosclerosis.
Although the exact role of HA is unknown, it is assumed to
lead to an increase in NO production through its role as a
substrate of NO synthase and a substrate for arginase, which
leads to increased arginine availability for NO synthase to
produce NO (35). In animal models, tamoxifen caused NO-
mediated vasodilatation (36-39) and reversed vascular
dysfunction caused by ovariectomy (40). The NO-mediated
effects may be responsible for the proposed cardioprotective
effect of tamoxifen, attributed to its ability to lower low-
density lipoprorein (LDL) and total cholesterol, cytokine-
mediated anti-inflammatory effects and anti-oxidant
properties, protecting LDL cholesterol from harmful
oxidation (7).
It is also widely accepted that NO also plays a role in
cardiotoxicity caused by chemotherapy, especially
anthracyclines. Cardiotoxicity is partially mediated by
anthracycline coupling with endothelial NO synthase,
leading to formation of radical oxygen species (41). The
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Figure 3. Homoarginine (HA) behavior in three trajectory groups in chemo-naïve patients. All tamoxifen users were included in groups 1 or 2.
Figure 4. The homoarginine (HA) level decreased during chemotherapy
and increased during radiotherapy (RT) in the group treated with
chemotherapy (CT).
behavior of HA, supported by the echocardiographic findings
shown in our study may be a reflection of these NO related
events in the endothelium.
Homoarginine and adjuvant breast cancer treatments. Our
study demonstrates HA behavior during adjuvant treatments
of breast cancer. To our knowledge, there are no previous
studies evaluating the effect of cancer therapies on the HA
level. In chemotherapy-naïve patients, the HA level of
tamoxifen users increased significantly, whereas that of AI
users or those without endocrine therapy remained stable
during RT. The baseline HA level of tamoxifen users was
also higher than that of non users, most likely due to starting
endocrine therapy prior to RT. A telephone query confirmed
that most patients had started tamoxifen prior to RT. The
trajectory model also supports the finding that tamoxifen
increases the HA level; all tamoxifen users were in the two
groups with the highest HA levels. 
The HA levels in chemo-naïve statin users increased
significantly, albeit slightly, during RT, whereas there was no
significant change in HA in patients without statin use. Statin
use was reported to have no effect on HA level (14) and its
usefulness as a predictor of cardiovascular and all-cause
mortality (11). As there were only 17 statin users, our findings
could be due to chance, but the possible effects of statin use
on HA level warrant further investigation as statins may have
a role as cardioprotectant during chemotherapy (42).
Adjuvant chemotherapy also affected the HA level. As
expected, due to adjuvant chemotherapy indications, patients
who received chemotherapy were younger and more likely to
receive tamoxifen or AI. During adjuvant RT, following
chemotherapy, the HA level increased but did not reach
starting levels in AI users, whereas in tamoxifen users, the HA
level returned to that at baseline, indicating a cardioprotective
effect of tamoxifen. The effect of statin use on HA level in
chemotherapy-receiving patients was not determined, as there
was only one statin-user receiving chemotherapy. 
Other biomarkers. The level of ADMA did not change
during adjuvant therapy. The ADMA level of patients
receiving chemotherapy was lower than that of chemo-naïve
patients, as ADMA tends to increase with age (43) and
patients treated with chemotherapy were younger than
chemo-naïve patients. ADMA appears to be insufficiently
sensitive for detecting cardiovascular risk in our patients.
Earlier, we reported that RT induced an increase of
hscTnT in chemo-naïve patients with left-sided breast cancer
that was associated with cardiac radiation dose (21). In
patients with chemotherapy, hscTnT increased during both
chemotherapy and RT significantly. Some evidence of the
possible cardioprotective effect of tamoxifen was also seen
in hscTnT behavior, as during RT, further increase of hscTnT
was only significant in AI users, not in tamoxifen users. 
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Changes in echocardiographic measurements. RT-induced
changes in echocardiographic measurements of our chemo-
naïve patient population have been published previously (17,
21, 33, 34, 44). However, in this study, we reported the
differences in echocardiographic changes in chemo-naïve
patients according to endocrine therapy. The differences in
baseline echocardiographic parameters according to
endocrine therapy use are attributable to starting endocrine
therapy before starting RT. 
Patients using tamoxifen were spared most of the RT-
induced changes. Only CVIBS, a sensitive marker of left
ventricular systolic function, showed a significant decline
with RT. 
In AI users, there was a decline in TAPSE, a measurement
of right ventricular systolic function, and GLS, a
measurement of left ventricular myocardial performance,
both prognostic markers in various heart diseases (25, 45-
47). In addition, a decline in mitral E wave implies that
diastology was also affected. 
Patients without endocrine therapy exhibited structural
changes in addition to functional changes, as the left
ventricular wall thickened and its reflectivity increased after
RT. As in our previous work, these changes might represent
RT-induced tissue swelling as a result of early inflammatory
changes (17, 24, 33, 34, 44). The functional changes were
visible in ventricular function, namely, in TAPSE and CVIBS. 
The changes during RT in echocardiographic parameters
in chemo-naïve patients were similar to those we described
previously (17, 24, 33, 34, 44). This study only included
patients with measurable HA. Earlier, we reported a decrease
in CVIBS induced by AI (24), but the study included patients
excluded here due to missing serum samples. Furthermore,
the laterality of breast cancer was not taken into
consideration in our study. These facts might explain the
different findings.
The echocardiographic findings of patients with
chemotherapy in this population have not been previously
published. Structural changes, namely, thickening of the
ventricular wall, were seen during chemotherapy, as LVESD
and PW increased. Functional changes were limited to a
decline in the left ventricular systolic marker, CVIBS. A
significant increase in Trgrad was also measured, but this
cannot be considered clinically meaningful. RT, which was
received after chemotherapy, did not induce any additional
changes in echocardiography in these patients, but
chemotherapy-induced thickening of LVESD persisted even
after RT. Due to the small population that had both HA and
echocardiographic measurements, we were not able to
determine correlations between HA level and echocardio-
graphic measurements. 
Confounding factors and limitations. The small study
population is a major limitation of our study, especially the
small chemotherapy and tamoxifen-user groups. Therefore,
we were not able to determine the effect of laterality of
breast cancer on HA values, although the location of
myocardial changes due to RT is dependent on the irradiated
side. In the chemo-naïve patient population, tamoxifen and
AI users had a higher BMI than patients who did not use
endocrine therapy. A higher BMI has been associated with a
higher HA level (9, 11, 12), which could have influenced our
results. The concurrent use of endocrine therapy and RT
leads to inability to separate the effects of these different
treatments on echocardiographic parameters and biomarker
measurements. Finally, the cardiovascular complications of
adjuvant breast cancer treatments take years to manifest and
therefore larger studies, with longer follow-up, are needed to
confirm our results. 
Clinical implications. Due to the excellent results of early
breast cancer treatments, it is important to identify the
patients at risk for cardiovascular morbidity and mortality.
HA studies with longer follow-up could further elucidate the
mechanisms behind chemotherapy-induced cardiotoxicity
and the assumed cardioprotective effect of tamoxifen and
provide an additional, available and minimally invasive tool
to identify patients in need of cardiological follow-up. 
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